for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurinia Pharmaceuticals Inc

AUP.TO

Latest Trade

6.55CAD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.70

 - 

10.47

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Aurinia Reports Q2 2019 Results

Aug 6 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - INITIATING AUDREY™ PHASE 2/3 CLINICAL STUDY FOR VOS IN DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - FULLY-ENROLLED AURORA PHASE 3 TRIAL IN LUPUS NEPHRITIS CONTINUES ON TRACK WITH RESULTS ANTICIPATED IN LATE 2019.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.17.

Aurinia Pharmaceuticals Inc Qtrly Loss Per Share $0.14

May 14 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.14.AURINIA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $144.3 MILLION AS OF MARCH 31, 2019.

Iljin SNT Co Says Now "Seriously Considering" Whether To Nominate New Directors To Aurinia's Board

April 8 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::ILJIN SNT CO LTD SAYS NOW "SERIOUSLY CONSIDERING" WHETHER TO NOMINATE NEW DIRECTORS TO AURINIA'S BOARD.ILJIN SNT SAYS CONSIDERING WHETHER TO BUY MORE SECURITIES OF AURINIA PHARMACEUTICALS IN OPEN MARKET DEALS, PRIVATE TRANSACTIONS/OTHERWISE.ILJIN SNT SAYS CHIN KYU HUH REPORTS 14.5 PERCENT STAKE IN AURINIA PHARMACEUTICALS AS OF FEB 14 - SEC FILING.

Aurinia Qtrly Loss Per Share $0.17

March 19 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $125.9 MILLION AS OF DECEMBER 31, 2018..AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.17.

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Superior Efficacy In A Phase 2 Head-To-Head Study

Jan 22 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA ANNOUNCES VOCLOSPORIN OPHTHALMIC SOLUTION DEMONSTRATES STATISTICALLY SUPERIOR EFFICACY VERSUS RESTASIS® IN A PHASE 2 HEAD-TO-HEAD STUDY FOR THE TREATMENT OF DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - PRIMARY ENDPOINT OF DROP DISCOMFORT AT 1-MINUTE ON DAY 1 SHOWED NO STATISTICAL DIFFERENCE BETWEEN VOS AND RESTASIS.AURINIA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED IN STUDY, AND THERE WERE NO UNEXPECTED SAFETY SIGNALS..

Aurinia Pharmaceuticals Richard Glickman, Chairman And Chief Executive Officer, To Retire

Nov 8 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS THIRD QUARTER FINANCIAL RESULTS, CLINICAL HIGHLIGHTS AND CORPORATE DEVELOPMENT.AURINIA PHARMACEUTICALS INC - RICHARD M. GLICKMAN, COMPANY'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER, INTENDS TO RETIRE.AURINIA PHARMACEUTICALS - GLICKMAN TO RETIRE AS CEO ONCE A REPLACEMENT IS IDENTIFIED AND APPOINTED.AURINIA PHARMACEUTICALS INC - AT SEPTEMBER 30, 2018, WE HAD CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS OF $138.9 MILLION.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.21.

Aurinia Completes Enrollment Of Aurora, Its Phase 3 Clinical Trial For The Treatment Of Lupus Nephritis

Sept 25 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA PHARMACEUTICALS INC - COMPANY ANTICIPATES PRIMARY DATA ANALYSIS IN Q4 2019.

Aurinia Pharmaceuticals Qtrly Loss Per Share $0.19

Aug 9 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS SECOND QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.19.AURINIA PHARMACEUTICALS INC - AT JUNE 30, 2018, CO HAD CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS OF $150.2 MILLION.AURINIA PHARMACEUTICALS-HAVE SUFFICIENT RESOURCES TO FUND EXISTING LN PROGRAM, CONDUCT PHASE II TRIALS FOR FSGS AND DES, AND FUND OPERATIONS INTO 2020.AURINIA PHARMACEUTICALS INC - AURORA PHASE III TRIAL IN LUPUS NEPHRITIS ANTICIPATED TO COMPLETE ENROLLMENT AHEAD OF SCHEDULE.

Aurinia Reports Qtrly Loss Per Share $0.18

May 10 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - AURORA PHASE III TRIAL IN LUPUS NEPHRITIS REMAINS ON TRACK.AURINIA PHARMACEUTICALS INC - CONTINUE TO BE WELL-CAPITALIZED INTO 2020.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.18.

Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​

March 15 (Reuters) - Aurinia Pharmaceuticals Inc <AUP.TO>::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE ‍$0.04​.AURINIA PHARMACEUTICALS INC - ‍TRIALS IN FSGS AND DRY EYE TO BEGIN IN Q2 2018​.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up